-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KCtXJfDie3vL3V2DDglyOtY+2cnnaUyQNZuMBXyy52jhROWdc8xd0A/+FYhZG5uZ oJ4Cqybmu053Pe0ZN7nRSQ== 0000912057-02-021503.txt : 20020522 0000912057-02-021503.hdr.sgml : 20020522 20020521181730 ACCESSION NUMBER: 0000912057-02-021503 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20020508 ITEM INFORMATION: Changes in registrant's certifying accountant ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 20020522 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIO TECHNOLOGY GENERAL CORP CENTRAL INDEX KEY: 0000722104 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 133033811 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-15313 FILM NUMBER: 02659224 BUSINESS ADDRESS: STREET 1: 70 WOOD AVE S CITY: ISELIN STATE: NJ ZIP: 08830 BUSINESS PHONE: 9086328800 MAIL ADDRESS: STREET 1: 70 WOOD AVENUE SOUTH CITY: ISELIN STATE: NJ ZIP: 08830 8-K/A 1 a2080757z8-ka.txt 8-K/A - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): MAY 8, 2002 BIO-TECHNOLOGY GENERAL CORP. (Exact name of issuer as specified in its charter) DELAWARE 0-15313 13-3033811 (State or Other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No.) 70 WOOD AVENUE SOUTH ISELIN, NEW JERSEY 08830 (Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (732) 632-8800 NONE. (Former address, if changed since last report.) - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- ITEM 4. CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT. The Audit Committee of the Board of Directors of Bio-Technology General Corp. (the "Company") annually considers and recommends to the Board the selection of the Company's independent public accountants. As recommended by the Company's Audit Committee, the Company's Board of Directors on May 8, 2002 decided to dismiss Arthur Andersen LLP ("Arthur Andersen") as the Company's independent public accountants and engaged KPMG LLP ("KPMG") to serve as the Company's independent public accountants for 2002. During the Company's two most recent fiscal years ended December 31, 2000 and 2001, and through May 8, 2002, there were no disagreements between the Company and Arthur Andersen on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to Arthur Andersen's satisfaction, would have caused Arthur Andersen to make reference to the subject matter of the disagreement in connection with its reports. None of the reportable events described under Item 304(a)(1)(v) of Regulation S-K occurred within the Company's two most recent fiscal years ended December 31, 2000 and 2001 or through May 8, 2002. The audit reports of Arthur Andersen on the consolidated financial statements of the Company as of and for the fiscal years ended December 31, 2000 and 2001 did not contain any adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope or accounting principles. The Company provided Arthur Andersen with a copy of this Form 8-K/A. Attached as Exhibit 16.1 to this Form 8-K/A is a copy of Arthur Andersen's letter, dated May 20, 2002, stating its agreement with the statements concerning Arthur Andersen. During the Company's two most recent fiscal years ended December 31, 2000 and 2001, and through May 8, 2002, neither the Company, nor anyone acting on its behalf, consulted with KPMG with respect to the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company's consolidated financial statements, or any other matters or events set forth in Item 304(a)(2)(i) and (ii) of Regulation S-K. Although Arthur Andersen has served as the Company's principal auditor, KPMG Somekh Chaikin has audited the statutory financial statements of Bio-Technology General (Israel) Ltd., the Company's wholly-owned Israeli subsidiary, for more than the last two fiscal years. ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS. (a) Financial Statements of Business Acquired. None. (b) Pro Forma Financial Information. None. (c) Exhibits. 16.1 Letter, dated May 20, 2002, from Arthur Andersen LLP to the Securities and Exchange Commission. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. BIO-TECHNOLOGY GENERAL CORP. (Registrant) By: /s/ JOHN BOND ----------------------------------------- John Bond Senior Vice President-Finance
Dated: May 21, 2002 EX-16.1 3 a2080757zex-16_1.txt EX 16.1 EXHIBIT 16.1 May 20, 2002 Office of the Chief Accountant Securities and Exchange Commission 450 Fifth Street, N.W. Washington, D.C. 20549 Dear Sir/Madam: We have read the second sentence of the first paragraph of Item 4 and the second through fourth paragraphs of Item 4 included in the Form 8-K/A dated May 8, 2002 of Bio Technology General Corp. to be filed with the Securities and Exchange Commission and are in agreement with the statements contained therein. Very truly yours, /s/ Arthur Andersen LLP Arthur Andersen LLP cc: Mr. John Bond Senior Vice President - Finance, Bio-Technology General Corp. -----END PRIVACY-ENHANCED MESSAGE-----